博士，研究员，博士生导师，博士后合作导师，国家高层次青年人才、四川省高层次青年人才，华西医院临床药学部（药剂科）副主任、临床药学室组长，华西医院临床药学研究所副所长，比利时鲁汶大学兼职教授（scientific collaborator）/博士生导师。任四川省医学会临床药学专委会青年副主委等。博士毕业于比利时鲁汶大学鲁汶药物研究所，曾任英国剑桥大学代谢科学研究所、鲁汶大学鲁汶药物研究所博士后、项目研究员。主要从事重大慢病的防治研究，聚焦代谢性疾病和胃肠道疾病等。相关研究成果以通讯作者/第一作者在国际权威学术期刊Science Advances、Gut、Endocrine Reviews、ACS Nano、Bioactive Materials、Advanced Drug Delivery Reviews、Biomaterials、Journal of Controlled Release等发表。主要科研成果申请国际PCT专利，并获欧洲学术委员会临床专项转化基金的支持。多次获邀在国际知名学术会议进行学术报告。主要科研项目包括国家自然科学基金优秀青年科学基金（海外）、国家科技创新2030“四大慢病”重大专项课题、国家自然科学基金国际合作与交流项目、国家自然科学基金面上项目、四川省科技厅重点项目、比利时国家科学基金FNRS-ASP基金、比利时国家科学基金FNRS-CR基金等。获国际控释协会（CRS）口服递送分会青年科学家奖、多项欧洲学术委员会奖励、欧洲药剂学2020最杰出博士文论奖（唯一）、比利时交叉学科2020最佳博士论文奖等。
注：1. 本课题组常年招收博士后、（稳定）科研助理，要求具药学类、生物技术与生物科学、化学、材料、工程、免疫学等相关背景。请有意向者请将个人简历、过往研究内容概述、拟开展研究方向概述、近五年发表论文等资料发送至邮箱：yiningxu@scu.edu.cn
邮件主题请标注：博士后/科研助理申请+姓名+专业+毕业（在读）院校+联系电话
2. 本课题组每年招收博士、硕士研究生，欢迎热爱科研的同学到课题组学习，联系邮箱：yiningxu@scu.edu.cn
1. 四川省医学会临床药学专业委员会青年委员会副主任委员等
2. Pharmaceutics，客座编辑，IF=5.4；四川大学学报（医学版）青年编委等
3.长期担任特邀审稿人为Journal of Hematology & Oncology, Advanced Functional Materials, Journal of Controlled Release, Small, Acta Biomaterialia, Molecular Therapy, Acta Pharmaceutica Sinica B, Journal of Nanobiotechnology, Advanced NanoBiomed Research, ACS Applied Materials & Interfaces等高水平期刊杂志进行同行评审。
主要科研项目：
1. 国家自然科学基金国际交流与合作项目
2. 国家科技创新2030“四大慢病”重大专项课题
3. 国家自然科学基金面上项目
4. 国家自然科学基金优秀青年科学基金项目（海外）
5. 四川省科技厅重点项目（国际合作）
6. 比利时国家科学基金FNRS-CR
7. 比利时国家科学基金FNRS-ASP
8. 比利时地区政府杰出青年科学家项目
9. 欧洲研究委员会欧盟“2020地平线”框架计划重点项目
10. 比利时国家科学基金重点项目
科研论文（*通讯作者）：
2026
34. Xiang You1, Jingjing Ma1, Ling Zou, Yutong Shu, Zhilong Jia, Yajin Kang, Yu Wang, Xin Xiao, Ziting Ma, Jinhan He, Yining Xu*. Restoring immunoglobulin A/polymeric immunoglobulin receptor transport axis for the oral treatment of inflammatory bowel disease. Journal of Controlled Release, 2026, 115002. (IF: 12.4)
33. Yining Xu*, Daniel J Drucker*, Giovanni Traverso*, Ana Beloqui*. Innovative molecules and delivery technologies enabling the future of GLP-1-based therapies. Endocrine Reviews, 2026, 47(1), 1-23. (IF: 23.9) (亮点推荐论文)
32. Yu Wang1, Cheng Chen1, Xin Xiao, Yajing Kang, Jinhan He, Ana Beloqui*, Yining Xu*. Advanced oral therapies for colorectal cancer via nanomedicine and microbiota modulation. Advanced Drug Delivery Reviews, 2026, 228, 115741. (IF: 21.0)
31. Ling Zou, Xiang You, Jingjing Ma, Chuanlan Liu, Xiaokun Shang, Zhilong Jia, Huile Gao, Jinhan He, Lian Li*, Yining Xu*. Advances in non-invasive delivery strategies for anti-cancer therapy. Journal of Controlled Release, 2026, 393, 114773. (IF: 12.4)
30. Cheng Chen, Léo Guilbaud, Valentina Marotti, Wunan Zhang, Inês Domingues, Hafsa Yagoubi, Katlijn Vints, Yining Xu*, Ana Beloqui*. An antioxidant metal-organic framework with functional coatings for oral anti-TNF-α antibody delivery in inflammatory bowel disease treatment. Journal of Controlled Release, 2026, 389, 114411. (IF: 12.4)
29. Qin Tang, Juan Pang, Jinhang Zhang, Qinhui Liu, Jiahui Li, Ailin Zhang, Ying Xu, Haiying Song, Haifeng Zeng, Xiandan Jing, Na Yang, Yimin Xiong, Zijing Zhang, Yining Xu, Yanping Li, Li Mo*, Jinhan He*. TOX3 in hypothalamic POMC-lineage cells regulates energy balance via the PTEN-AKT signaling axis. Nature Communications, 2026, 17, 5062. (IF: 18.1)
28. Qin Tang, Jiahui Li, Haiying Song, Ailin Zhang, Haifeng Zeng, Yining Xu, Li Mo*, and Jinhan He*. Hypothalamic Control of Liver Health and Disease: From Circuits to Pathophysiology and Therapies. Advanced Science, 2026, accepted. (IF:14.1)
27. Wenjing Wang, Qiang He, Tianfei Fan, Yang Xiong, Yimin Xiong, Qinhui Liu, Na Yang, Yining Xu, Yanping Li, Jinhan He*. An H4K12la/CEBPB-AKR1C2 signaling axis modulates the mTOR pathway to regulate cisplatin resistance in lung cancer. Oncogene, 2026, 45(5), 650-662. (IF: 9.1)
26. Ling Zou, Zhilong Jia, Yutong Shu, Xiang You, Jingjing Ma, Yu Wang, Jinhan He, Yining Xu*. Extracellular vesicles from pasteurized Akkermansia muciniphila ameliorate inflammatory bowel disease through suppression of STING-driven inflammatory signalling. Frontiers in Microbiology, 2026, accepted. (IF: 5.8)
25. Lanyu Gao, Qing Shao, Xinyu Zhuo, Yining Xu*, Yuwei Zhang*. Impact of glucokinase activators on the gut microbiota of high-fat diet-induced obese and type 2 diabetic mice. Frontiers in Microbiology, 2026, 19:17:1783385. (IF: 5.8)
24. Kaipeng Zhang, Tengfei Zhu, Yamin Wang, Jing Chen, Shan Xie, Zhenye Lin, Xiaotong Chen, Yingying Yu*, Yining Xu*. Size-Dependent Efficacy of Lipid Nanoparticles in Improving Glucose Utilization of Largemouth Bass (Micropterus salmoides) Under High-Glucose Conditions. Aquaculture Nutrition, 2026, 7025461. (IF: 4.6)
23. Jun Zhao, Qinhui Liu, Luyue Xie, Cuitong Wang, Yimin Xiong, Xinqi Liang, Ying Sun, Ying Xu, Haiying Song, Mingzhu Xu, Xiandan Jing, Yining Xu, Yanping Li, Li Mo, Juan Pang*, Jinhan He*. GLYAT deficiency protects against acetaminophen-induced liver injury by increasing glycine availability for glutathione synthesis. Biochemical Pharmacology, 251, 2026, 118084. (IF: 5.6)
2025
22. Junzhu Shi, Chendong Liu, Jiaqi Liu, Yue Yan, Fengju Wang, Shenao Yan, Yucheng Xiang*, Minglu Zhou*, Yining Xu*, Lian Li*. CXCR4 Clustering Induced by Polymeric Nanothreads Impedes Cancer Cell Metastasis via PIEZO1-Mediated Mechanotransduction. Advanced Healthcare Materials, 2025, 2501072. (IF: 11.0)
21. Qingyi Jia, Jinhang Zhang, Haiying Song, Jiahao Chen, Zhenyu Zhang, Huihui Yu, Yi Chen, Qinhui Liu, Xiandan Jing, Haixia Xu, Jingwei Li, Yimin Xiong, Meilin Ma, Na Yang, Junyan Li, Yining Xu, Yanping Li*, Jinhan He*. Neuroplastin-55 is a receptor of Manf and protects against diet-induced obesity by promoting adipose browning. PNAS, (2025):e2515526122. (IF:9.5)
20. Fan Yang, Dong Mo, Beibei Wu, Jiahao Chen, Qinhui Liu, Wenfei Chen, Juan Pang, Wenjing Wang, Xiandan Jing, Yimin Xiong, Na Yang, Yining Xu, Yanping Li, Yuan Huang, Li Mo, Jinhan He*. Photo-controlled multifunctional hydrogel for photothermal sterilization and microenvironment amelioration of infected diabetic wounds. Journal of Controlled Release, 322 (2025) 377:470-484. (IF: 12.4)
19. Qiuxia Jiao, Yuan Huang, Jinhan He, Yining Xu*. Advances in Oral Biomacromolecule Therapies for Metabolic Diseases. Pharmaceutics, 2025:17(2):238. (IF: 6.9) (特邀约稿)
2024
18. Yining Xu, Cécilia Bohns Michalowski, Jackie Koehler, Tamana Darwish, Nunzio Guccio, Constanza Alcaino, Inês Domingues, Wunan Zhang, Valentina Marotti, Matthias Van Hul, Paola Paone, Melitini Koutsoviti, Ben J Boyd, Daniel J Drucker, Patrice D Cani, Frank Reimann*, Fiona M Gribble*, Ana Beloqui*. Smart control lipid-based nanocarriers for fine-tuning gut hormone secretion. Science Advances, (2024): 10 (50), eadq9909. (IF: 12.5)
17. Valentina Marotti1, Yining Xu1, Cécilia Bohns Michalowski1, Wunan Zhang, Inês Domingues, Hafsa Ameraoui, Tom G Moreels, Pieter Baatsen, Matthias Van Hul, Giulio G Muccioli, Patrice D Cani, Mireille Alhouayek, Alessio Malfanti, Ana Beloqui*. A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment. Bioactive Materials, 32 (2024) 206-221. (共同一作) (IF: 20.3)
16. Emilie Moens de Hase, Audrey M Neyrinck, Julie Rodriguez, Miriam Cnop, Nicolas Paquot, Jean-Paul Thissen, Yining Xu, Ana Beloqui, Laure B Bindels, Nathalie M Delzenne, Matthias Van Hul*, Patrice D Cani*. Impact of metformin and Dysosmobacter welbionis on diet-induced obesity and diabetes: from clinical observation to preclinical intervention. Diabetologia, (2024):67(2):333-345. (IF: 10.2)
15. Wunan Zhang, Fiona McCartney, Yining Xu, Cécilia Bohns Michalowski, Inês Domingues, Espoir K Kambale, Tom G Moreels, Léo Guilbaud, Cheng Chen, Valentina Marotti, David J Brayden, Ana Beloqui*. An in situ bioadhesive foam as a large intestinal delivery platform for antibody fragment to treat inflammatory bowel disease. Journal of Controlled Release, (2024) 374:254-266. (IF: 11.5)
2023
14. Cheng Chen, Ana Beloqui*, Yining Xu*. Oral nanomedicine biointeractions in the gastrointestinal tract in health and disease. Advanced Drug Delivery Reviews, (2023): 115117. (IF: 16.1)
加入四川大学以前：
13. Yining Xu, Thibaut Fourniols1, Yasmine Labrak1, Véronique Préat, Ana Beloqui*, Anne des Rieux*. Surface Modification of Lipid-Based Nanoparticles. ACS NANO, 16 (2022) 7168-7196. (IF: 18.027)
12. Neha Shrestha*, Yining Xu, Julien R C Prévost, Fiona McCartney, David Brayden, Raphaël Frédérick, Ana Beloqui, Véronique Préat*. Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease. Acta Biomaterialia, 140 (2022) 561-572. (IF: 10.633)
11. Yining Xu, Neha Shrestha1, Véronique Préat*, Ana Beloqui*. An overview of in vitro, ex vivo and in vivo models for studying the transport of drugs across intestinal barriers. Advanced Drug Delivery Reviews, 175 (2021): 1137952. (IF: 17.873)
10. Yining Xu, Cecilia Bohns Michalowsk, and Ana Beloqui*. Advances in lipid carriers for drug delivery to the gastrointestinal tract. Current Opinion in Colloids & Interface Science, 52 (2021):101414. (IF: 8.209)
9. Yining Xu, Herlinde De Keersmaecker, Kevin Braeckmans, Stefaan De Smedt, Patrice D. Cani, Véronique Préat, Ana Beloqui*. Targeted nanoparticles towards increased L cell stimulation as a strategy to improve oral peptide delivery in incretin-based diabetes treatment. Biomaterials, 255 (2020) 120209. (IF: 15.304)
8. Yining Xu, Matthias van Hul, Francesco Suriano, Véronique Préat, Patrice D. Cani*, Ana Beloqui*. Novel strategy for oral peptide delivery in incretin-based diabetes treatment. Gut, 69 (2020) 911-919. (IF: 31.793) (入选Gut高影响论文)
7. Yining Xu, Neha Shrestha, Véronique Préat, Ana Beloqui*. Overcoming the intestinal barrier: A look into targeting approaches for improved oral drug delivery systems. Journal of Controlled Release, 322 (2020) 486-508. (IF: 11.467)
6. Amaia Huguet-Casquero, Yining Xu, Eusebio Gainza, Jose Luis Pedraz*, Ana Beloqui*. Oral delivery of oleuropein-loaded lipid nanocarriers alleviates inflammation and oxidative stress in acute colitis. International Journal of Pharmaceutics, 586 (2020) 119515. (IF: 5.875)
5. Yining Xu1, Yaxian Zheng1, Lei Wu, Xi Zhu, Zhirong Zhang, Yuan Huang*. A novel solid lipid nanoparticle with endosomal escaping function for oral insulin delivery. ACS Applied Materials & Interfaces, 10 (2018) 9315-9324. (IF: 8.456)
4. Yining Xu, Dario Carradori, Mireille Alhouayek, Giulio G. Muccioli, Patrice D. Cani, Véronique Préat *, Ana Beloqui*. Size effect on lipid nanocapsules-mediated GLP-1 secretion from enteroendocrine L cells. Molecular Pharmaceutics, 15 (2018) 108-115. (IF: 5.364)
3. Yining Xu, Juan Xu, Wei Shan, Min Liu, Yi Cui, Lian Li, Chong Liu, Yuan Huang*. The transport mechanism of integrin αvβ3 receptor targeting nanoparticles in Caco-2 cells. International Journal of Pharmaceutics, 500 (2016) 42-53. (IF: 5.875)
2. Chong Liu, Wei Shan, Min Liu, Xi Zhu, Juan Xu, Yining Xu, Yuan Huang*. A novel ligand conjugated nanoparticles for oral insulin delivery. Drug Delivery, 23 (2016) 2015-2025. (IF: 6.402)
1. Peiwen Zhang1, Yining Xu1, Xi Zhu, Yuan Huang*. Goblet Cell Targeting Nanoparticle containing Drug-loaded Micelle Cores for Oral Delivery of Insulin. International Journal of Pharmaceutics, 496 (2015) 993-1005. (共同一作) (IF: 5.875)
研究生部公众号
川公网安备51010702002012